Account Login
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Global Blood Ther (NQ: GBT )

25.68 -1.09 (-4.07%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 24, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 832,420
Open 26.44
Bid (Size) 25.75 (1)
Ask (Size) 26.17 (1)
Prev. Close 26.77
Today's Range 25.39 - 26.62
52wk Range 22.67 - 41.73
Shares Outstanding 65,098,164
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Global Blood Therapeutics Earnings Perspective: Return On Capital Employed
According to data from Benzinga Pro, during Q1, Global Blood Therapeutics's (NASDAQ:GBT) reported sales totaled $55.16 million. Despite a 7.03% increase in earnings, the company posted a loss of $81.42... 
Via Benzinga
Recap: Global Blood Therapeutics Q1 Earnings
Global Blood Therapeutics (NASDAQ:GBT) reported its Q1 earnings results on Wednesday, May 4, 2022 at 04:05 PM. Here's what investors need to know about the announcement. 
Via Benzinga

Performance

YTD
-15.69%
-15.69%
1 Month
-26.29%
-26.29%
3 Month
-17.75%
-17.75%
6 Month
-15.86%
-15.86%
1 Year
-31.02%
-31.02%

More News

Read More
Looking Into Global Blood Therapeutics's Return On Capital Employed
Via Benzinga
What 4 Analyst Ratings Have To Say About Global Blood Therapeutics
Via Benzinga
Recap: Global Blood Therapeutics Q4 Earnings
Via Benzinga
The Daily Biotech Pulse: Kodiak Sinks On Adverse Study Outcome, Marinus Flags Delay In Clinical Trial, Mainz Biomed Gains On Positive Regulatory Development
Via Benzinga
The Week Ahead In Biotech (Feb. 20-26): Reata Awaits FDA Decision, Bausch Health, Moderna Lead Earnings News Flow
Via Benzinga
The Daily Biotech Pulse: Avenue Tumbles On Negative Adcom Verdict, Moderna's Expanded Deal With Rovi, Gilead Takes Equity Stake In Hookipa
Via Benzinga
Stock Wars: Axsome Therapeutics Vs. Global Blood Therapeutics
Via Benzinga
The Journey To Rewrite Human DNA Is About To Get Wild, Thanks To Pfizer, Bayer, Intellia And Other CRISPR stocks
Via Investor's Business Daily
FDA Expands Use Of Global Blood' Sickle Cell Treatment To Kids Aged 4-12 Years
Via Benzinga
12 Health Care Stocks Moving In Friday's After-Market Session
Via Benzinga
Global Blood Raises $300M Via Convertible Debt Offering
Via Benzinga
50 Biggest Movers From Yesterday
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Global Blood Therapeutics Earnings Perspective: Return On Capital Employed
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For December 7, 2021
Via Benzinga
Attention Biotech Investors: Mark Your Calendar For December PDUFA Dates
Via Benzinga
Exposures Product Safety
The Week Ahead In Biotech (Dec. 6-Dec. 11): Daré FDA Decision, Adcom Tryst For Reata, Multiple Conference Presentations And More
Via Benzinga
Exposures Product Safety
Global Blood Therapeutics (GBT) Q3 2021 Earnings Call Transcript
Via The Motley Fool
Topics Earnings
Exposures Financial
The Daily Biotech Pulse: Merck's Oral COVID-19 Pill Authorized In UK, Novartis Cashes Out Of Roche, Chimerix Plunges On Data, Evotec IPO
Via Benzinga
Exposures COVID-19
See Why Jefferies Sees Massive Upside In Global Blood Therapeutics
Via Benzinga
The Week Ahead In Biotech (Oct. 31-Nov. 6): Earnings Pick Up Pace, Eton Awaits Seizure Drug Approval, Kidney Conference, More IPOs In The Pipeline
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For October 7, 2021
Via Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.